Celgene (CELG) Release: Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients With Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes
4/26/2013 10:17:12 AM
More...
|
Celgene (Summit, New Jersey) (CELG) Completes Acquisition of Abraxis BioScience, Inc.
10/15/2010 11:03:55 AM
More...
|
Celgene Corporation (CELG) Elects James J. Loughlin To Board Of Directors
1/8/2007 2:43:09 PM
More...
|
Drug's Effect On Cancer Stuns Doctors
10/19/2005 5:10:07 PM
More...
|
Celgene Corporation (CELG) Release: FDA Grants Priority Review For REVLIMID(R) NDA For Treatment Of Low- And Intermediate- Risk MDS With Deletion 5q Chromosomal Abnormality
10/19/2005 5:09:19 PM
More...
|